Journal of Medicinal Chemistry · 2018 · 26 citations · 34 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryMolecular PharmacologyNeuropharmacologyAnalgesic PharmacologyCannabinoid PharmacologyDrug-metabolizing EnzymesLigand BindingCannabinoid AgonistsCannabinoid AnalgesicsCannabinoid Receptor PharmacologyCannabinoid Structure-activity RelationshipsEndocannabinoid SystemLigand Binding AffinityLigand-receptor AffinityReceptor-ligand Binding Affinity
The synthesis of potent metabolically stable endocannabinoids is challenging. Here we report a chiral arachidonoyl ethanolamide (AEA) analogue, namely, (13S,1′R)-dimethylanandamide (AMG315, 3a), a high affinity ligand for the CB1 receptor (Ki of 7.8 ± 1.4 nM) that behaves as a potent CB1 agonist in vitro (EC50 = 0.6 ± 0.2 nM). (13S,1′R)-dimethylanandamide is the first potent AEA analogue with significant stability for all endocannabinoid hydrolyzing enzymes as well as the oxidative enzymes COX-2. When tested in vivo using the CFA-induced inflammatory pain model, 3a behaved as a more potent analgesic when compared to endogenous AEA or its hydrolytically stable analogue AM356. This novel analogue will serve as a very useful endocannabinoid probe.
34
Crystal Structure of the Human Cannabinoid Receptor CB1
Tian Hua, Kiran Vemuri, Mengchen Pu et al. · Cell · 2016 · 678 citations · Full text
RETRACTED ARTICLE: Crystal structures of agonist-bound human cannabinoid receptor CB1
Tian Hua, Kiran Vemuri, Spyros P. Nikas et al. · Nature · 2017 · 505 citations · Full text